Biotech News Pulse (INCY, DNDN, SQNM, ARNA)

Los Angelas, CA -- (SBWIRE) -- 01/14/2013 -- Incyte Corporation (NASDAQ:INCY) is +0.95 - +5.22% from the previous close of $18.20. It traded between $18.68 - 19.44 with total traded volume of 1492540 shares. At Current Market Price, INCY is in distance of +10.58% from its 50-day Moving Average price of $17.3174 and +0.08% from its 200-day Moving Average price of $19.1342.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

How Should Investors React To INCY Now? Find Out Here

Dendreon Corp. (NASDAQ:DNDN) are up 3.41% to $6.38 in trading volume of 8.3 million shares. The biotechnology company’s shares are on optimism for higher demand for Provenge, the company’s prostate-cancer drug. The 52-week high is $17.04.

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers.

How Should Investors Trade DNDN Now? Find Out Here

Sequenom, Inc. (NASDAQ:SQNM) reported the gain of +0.83% to close at $4.23 and its total traded volume was 7.21 million shares in the last trading session. Sequenom, Inc. (SQNM), a life sciences company providing advanced indicative testing and genetic study solutions, declared initial highlights of the Company’s 2012 accomplishments.

Sequenom provides genetic analysis products that translate genomic science into solutions for biomedical research, molecular medicine and agricultural applications.

Is SQNM Showing Any Sign of Buy At The Current Market Price? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is +0.52 - +5.38% from the previous close of $9.66. It traded between $9.65 - 10.26 with total traded volume of 9523607 shares. Keep a close eye on ARNA, as the stock has been showing unusual moves over the past weeks. At Current market price, ARNA has recovered +561.04% from its 52-week Low of 1.54 and has Pulled back -24.59% from its 52-week high of 13.50.

Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

How Should Investors Trade ARNA After The Recent Volatile Moves? Find Out Here

DISCLAIMER
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com